Ligand ID: ZPC


Drugbank ID:
DB00402
(Eszopiclone)
DB01198
(Zopiclone)


Indication:
For the treatment of insomnia;For the short-term treatment of insomnia.

Get human targets for ZPC in PDB (known and potential targets)

RESULTS FROM SUB-STRUCTURAL SIMILARITY SEARCHES MAPPED TO LIGAND 'ZPC' AND SARS-COV-2 / COVID-19 STRUCTURES

1) User may click on the DrReposER ID (the first column) to get information on the binding sites and drug molecule.
2) Click View (the second last column) to view matched residues and superposition in the NGL viewer (upper right part).
3) User may also click on the Dock (the last column) to get script for molecular docking in UCSF Chimera throuh AutoDock Vina.

DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 View Interface RMSD Seq.
Identity (%)		 HETATM Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.67A19.48
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.71A19.48
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.59A19.48
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 7
ILE A 200
PHE A 291
HIS A 172
VAL A 125
1.65A19.48
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 7
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.66A19.48
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6lze VIRAL PROTEASE
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.73A20.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6lze VIRAL PROTEASE
(SARS-CoV-2)		4 / 7
ILE A 106
TYR A 182
HIS A 164
PHE A 134
1.73A20.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6lze VIRAL PROTEASE
(SARS-CoV-2)		4 / 7
GLU A 178
PHE A 103
HIS A  80
VAL A  91
1.47A20.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6lze VIRAL PROTEASE
(SARS-CoV-2)		4 / 7
GLU A 288
GLU A 290
PHE A 291
VAL A 125
1.58A20.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6lze VIRAL PROTEASE
(SARS-CoV-2)		4 / 7
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.69A20.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6lze VIRAL PROTEASE
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.70A20.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6lze VIRAL PROTEASE
(SARS-CoV-2)		4 / 6
GLU A 178
PHE A 103
HIS A  80
VAL A  91
1.65A20.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6lze VIRAL PROTEASE
(SARS-CoV-2)		4 / 6
ILE A 200
PHE A 291
HIS A 172
VAL A 125
1.72A20.88
None
None
ELL  D   3 (-4.6A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6lze VIRAL PROTEASE
(SARS-CoV-2)		4 / 7
ILE A 200
PHE A 291
HIS A 172
VAL A 125
1.61A20.88
None
None
ELL  D   3 (-4.6A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6lze VIRAL PROTEASE
(SARS-CoV-2)		4 / 7
GLU A 178
TYR A 101
VAL A  18
PHE A 159
1.73A20.88
None
None
DMS  A 403 ( 4.9A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6lze VIRAL PROTEASE
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.61A20.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m0j SPIKE RECEPTOR
BINDING DOMAIN
(SARS-CoV-2)		4 / 6
GLU E 516
PHE E 515
TYR E 396
VAL E 341
1.61A21.91
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m0k VIRAL PROTEASE
(SARS-CoV-2)		4 / 7
GLU A 178
PHE A 103
HIS A  80
VAL A  91
1.47A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m0k VIRAL PROTEASE
(SARS-CoV-2)		4 / 7
GLU A 288
GLU A 290
PHE A 291
VAL A 125
1.57A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m0k VIRAL PROTEASE
(SARS-CoV-2)		4 / 7
GLU A 178
TYR A 101
VAL A  18
PHE A 159
1.72A20.82
None
None
DMS  A 401 ( 4.8A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m0k VIRAL PROTEASE
(SARS-CoV-2)		4 / 7
ILE A 106
TYR A 182
HIS A 164
PHE A 134
1.76A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m0k VIRAL PROTEASE
(SARS-CoV-2)		4 / 7
ILE A 200
PHE A 291
HIS A 172
VAL A 125
1.61A20.82
None
None
ELL  D   3 (-4.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m0k VIRAL PROTEASE
(SARS-CoV-2)		4 / 6
GLU A 178
PHE A 103
HIS A  80
VAL A  91
1.66A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m0k VIRAL PROTEASE
(SARS-CoV-2)		4 / 6
ILE A 200
PHE A 291
HIS A 172
VAL A 125
1.73A20.82
None
None
ELL  D   3 (-4.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 7
PHE D 159
TYR D 101
VAL D 157
ILE D 152
1.75A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 7
ILE D 200
PHE D 291
HIS D 172
VAL D 125
1.60A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
PHE C 159
TYR C 101
VAL C 157
ILE C 152
1.78A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 6
ILE D 200
PHE D 291
HIS D 172
VAL D 125
1.73A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 7
ILE C 106
TYR C 182
HIS C 164
PHE C 134
1.74A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 7
PHE B 159
TYR B 101
VAL B 157
ILE B 152
1.70A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
PHE B 159
TYR B 101
VAL B 157
ILE B 152
1.58A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
PHE C 140
TYR C 118
MET C  17
ASN C  28
1.72A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.67A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.70A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
PHE D 140
TYR D 118
MET D  17
ASN D  28
1.69A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
PHE D 159
TYR D 101
VAL D 157
ILE D 152
1.80A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 7
ILE C 200
PHE C 291
HIS C 172
VAL C 125
1.60A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.58A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 7
PHE C 159
TYR C 101
VAL C 157
ILE C 152
1.76A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 7
PHE B 159
TYR B 101
VAL B 157
ILE B 152
1.65A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
PHE B 159
TYR B 101
VAL B 157
ILE B 152
1.71A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 7
GLU A 288
GLU A 290
PHE A 291
VAL A 125
1.71A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 7
ILE A 106
TYR A 182
HIS A 164
PHE A 134
1.77A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 7
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.65A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
PHE C 159
TYR C 101
VAL C 157
ILE C 152
1.68A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
PHE D 159
TYR D 101
VAL D 157
ILE D 152
1.76A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 7
ILE A 200
PHE A 291
HIS A 172
VAL A 125
1.56A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 7
GLU B 288
GLU B 290
PHE B 291
VAL B 125
1.69A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
PHE D 159
TYR D 101
VAL D 157
ILE D 152
1.67A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 7
GLU A 288
GLU A 290
PHE A 291
VAL A 125
1.66A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 7
PHE D 159
TYR D 101
VAL D 157
ILE D 152
1.79A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
PHE B 159
TYR B 101
VAL B 157
ILE B 152
1.70A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
PHE B 159
TYR B 101
VAL B 157
ILE B 152
1.67A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 7
GLU B 288
GLU B 290
PHE B 291
VAL B 125
1.65A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 7
ILE B 200
PHE B 291
HIS B 172
VAL B 125
1.56A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 7
ILE D 106
TYR D 182
HIS D 164
PHE D 134
1.73A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 7
ILE B 106
TYR B 182
HIS B 164
PHE B 134
1.77A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
PHE D 159
TYR D 101
VAL D 157
ILE D 152
1.80A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2q 3CL PROTEASE
(SARS-CoV-2)		4 / 7
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.72A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2q 3CL PROTEASE
(SARS-CoV-2)		4 / 7
ILE A 106
TYR A 182
HIS A 164
PHE A 134
1.78A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2q 3CL PROTEASE
(SARS-CoV-2)		4 / 7
ILE A 200
PHE A 291
HIS A 172
VAL A 125
1.67A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2q 3CL PROTEASE
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.73A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2q 3CL PROTEASE
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.59A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2q 3CL PROTEASE
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.72A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2q 3CL PROTEASE
(SARS-CoV-2)		4 / 7
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.67A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2q 3CL PROTEASE
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.69A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m71 NSP12
(SARS-CoV-2)		4 / 7
PHE A 348
VAL A 535
ILE A 536
GLU A 350
1.51A15.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_C_ZPCC1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m71 NSP12
(SARS-CoV-2)		5 / 12
ILE A 632
ASN A 628
GLU A 665
TYR A 346
HIS A 347
1.73A15.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m71 NSP12
(SARS-CoV-2)		4 / 6
GLU A 136
TYR A 163
VAL A 174
PHE A 134
1.55A15.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m71 NSP8
(SARS-CoV-2)		4 / 8
PHE B 147
TYR B 149
VAL B 130
ILE B 132
1.76A19.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m71 NSP12
(SARS-CoV-2)		4 / 8
TYR A 915
MET A 906
ASN A 911
GLU A 919
1.55A15.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m71 NSP8
(SARS-CoV-2)		4 / 8
PHE B 147
TYR B 149
VAL B 130
ILE B 132
1.75A19.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m71 NSP8
(SARS-CoV-2)		4 / 7
PHE B 147
TYR B 149
VAL B 130
ILE B 132
1.73A19.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m71 NSP12
(SARS-CoV-2)		4 / 8
TYR A 915
MET A 906
ASN A 911
GLU A 919
1.74A15.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m71 NSP12
(SARS-CoV-2)		4 / 8
PHE A 480
VAL A 587
MET A 755
ILE A 757
1.57A15.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_B_ZPCB1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m71 NSP12
(SARS-CoV-2)		5 / 12
ILE A 632
ASN A 628
GLU A 665
TYR A 346
HIS A 347
1.69A15.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m71 NSP8
(SARS-CoV-2)		4 / 7
PHE B 147
TYR B 149
VAL B 130
ILE B 132
1.77A19.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m71 NSP12
(SARS-CoV-2)		4 / 8
PHE A 348
VAL A 535
ILE A 536
GLU A 350
1.68A15.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m71 NSP12
(SARS-CoV-2)		5 / 7
PHE A 348
VAL A 535
ILE A 536
ASN A 657
GLU A 350
1.60A15.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m71 NSP12
(SARS-CoV-2)		4 / 7
GLU A 136
TYR A 163
VAL A 174
PHE A 134
1.57A15.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m71 NSP12
(SARS-CoV-2)		5 / 8
PHE A 348
VAL A 535
ILE A 536
ASN A 657
GLU A 350
1.69A15.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m71 NSP8
(SARS-CoV-2)		4 / 8
PHE B 147
TYR B 149
VAL B 130
ILE B 132
1.75A19.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m71 NSP12
(SARS-CoV-2)		5 / 8
PHE A 348
VAL A 535
ILE A 536
ASN A 657
GLU A 350
1.64A15.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m71 NSP12
(SARS-CoV-2)		4 / 7
PHE A 348
VAL A 535
ILE A 536
ASN A 657
1.64A15.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m71 NSP8
(SARS-CoV-2)		4 / 8
PHE B 147
TYR B 149
VAL B 130
ILE B 132
1.80A19.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m71 NSP12
(SARS-CoV-2)		4 / 8
PHE A 480
VAL A 587
MET A 755
ILE A 757
1.58A15.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_F_ZPCF1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m71 NSP12
(SARS-CoV-2)		5 / 12
GLU A 665
TYR A 346
HIS A 347
ILE A 632
ASN A 628
1.66A15.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m71 NSP12
(SARS-CoV-2)		5 / 8
PHE A 348
VAL A 535
ILE A 536
ASN A 657
GLU A 350
1.67A15.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
GLU C 918
HIS B1083
VAL B1104
PHE B1121
1.67A14.43
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6vww URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 6
ILE B  72
PHE B 123
TYR B 179
VAL B 149
1.51A20.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6vxs NSP3
(SARS-CoV-2)		4 / 7
ILE B  69
TYR A  68
HIS A  94
VAL A  63
1.61A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6vxs NSP3
(SARS-CoV-2)		4 / 7
ILE B  69
TYR A  68
HIS A  94
VAL A  63
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6vxs NSP3
(SARS-CoV-2)		4 / 7
ILE B  69
TYR A  68
HIS A  94
VAL A  63
1.62A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6vxs NSP3
(SARS-CoV-2)		4 / 6
ILE B  69
TYR A  68
HIS A  94
VAL A  63
1.63A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
ILE B 896
PHE B 898
TYR B 904
VAL B 911
1.40A13.76
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 6
ILE B 896
PHE B 898
TYR B 904
VAL B 911
1.46A13.76
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_C_ZPCC1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
PHE B 898
ILE B 931
ASN B 928
ILE A1130
VAL B 722
1.57A13.76
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 6
ILE B 896
PHE B 898
TYR B 904
VAL B 911
1.48A13.52
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_C_ZPCC1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
PHE C 898
ILE C 931
ASN C 928
ILE B1130
VAL C 722
1.59A13.52
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
ILE C 896
PHE C 898
TYR C 904
VAL C 911
1.42A13.52
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w01 URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 7
GLU B 261
HIS B 235
VAL B 295
PHE B 264
1.43A20.44
None
CIT  B 408 (-4.2A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w01 URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 7
PHE A 233
TYR A 231
VAL A 304
GLU A 234
1.48A20.44
None
EDO  A 408 (-4.3A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		4 / 7
PHE C 490
ARG C 454
ILE C 468
GLU C 484
1.36A19.48
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		4 / 8
PHE C 490
ARG C 454
ILE C 468
GLU C 484
1.46A19.48
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		4 / 7
GLU C 516
PHE C 515
TYR C 396
VAL C 341
1.78A19.48
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		4 / 6
GLU C 516
PHE C 515
TYR C 396
VAL C 341
1.76A19.48
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		4 / 7
GLU C 516
PHE C 515
TYR C 396
VAL C 341
1.76A19.48
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		4 / 7
PHE C 490
ARG C 454
ILE C 468
GLU C 484
1.46A19.48
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		4 / 8
PHE C 490
ARG C 454
ILE C 468
GLU C 484
1.46A19.48
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		4 / 8
PHE C 490
ARG C 454
ILE C 468
GLU C 484
1.44A19.48
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		4 / 8
PHE C 490
ARG C 454
ILE C 468
GLU C 484
1.44A19.48
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w63 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 7
ILE A 200
PHE A 291
HIS A 172
VAL A 125
1.63A
None
None
X77  A 401 ( 4.6A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w63 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 7
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.69A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w63 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.70A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w63 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 6
ILE A 200
PHE A 291
HIS A 172
VAL A 125
1.73A
None
None
X77  A 401 ( 4.6A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w63 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.74A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w63 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.61A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w63 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 7
GLU A 288
GLU A 290
PHE A 291
VAL A 125
1.58A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w63 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.75A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w63 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 7
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.74A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w75 NSP16
(SARS-CoV-2)		4 / 8
PHE A6985
TYR A7009
VAL A6965
ILE A6967
1.64A17.83
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_C_ZPCC1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w75 NSP16
(SARS-CoV-2)		5 / 12
VAL A7087
ILE A7088
ASN A6920
GLU A7082
VAL A6894
1.70A17.83
None
None
FMT  A7106 ( 4.0A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w75 NSP16
(SARS-CoV-2)		4 / 8
PHE A6985
TYR A7009
VAL A6965
ILE A6951
1.80A17.83
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w75 NSP16
(SARS-CoV-2)		4 / 7
PHE C6985
TYR C7009
VAL C6965
ILE C6967
1.59A17.83
None
NA  C7103 ( 4.8A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_C_ZPCC1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w75 NSP16
(SARS-CoV-2)		5 / 12
VAL A7086
ILE A7088
ASN A6920
GLU A7082
VAL A6894
1.79A17.83
None
None
FMT  A7106 ( 4.0A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w75 NSP16
(SARS-CoV-2)		4 / 7
PHE C6985
TYR C7009
VAL C6965
ILE C6951
1.74A17.83
None
NA  C7103 ( 4.8A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w75 NSP16
(SARS-CoV-2)		4 / 8
PHE C6985
TYR C7009
VAL C6965
ILE C6967
1.61A17.83
None
NA  C7103 ( 4.8A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w75 NSP16
(SARS-CoV-2)		4 / 8
PHE C6985
TYR C7009
VAL C6965
ILE C6951
1.72A17.83
None
NA  C7103 ( 4.8A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w75 NSP16
(SARS-CoV-2)		4 / 7
PHE A6985
TYR A7009
VAL A6965
ILE A6967
1.61A17.83
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w75 NSP16
(SARS-CoV-2)		4 / 8
PHE A6985
TYR A7009
VAL A6965
ILE A6967
1.63A17.83
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_C_ZPCC1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w75 NSP16
(SARS-CoV-2)		5 / 12
VAL C7087
ILE C7088
ASN C6920
GLU C7082
VAL C6894
1.69A17.83
None
None
FMT  C7106 ( 4.1A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w75 NSP16
(SARS-CoV-2)		4 / 8
PHE C6985
TYR C7009
VAL C6965
ILE C6967
1.62A17.83
None
NA  C7103 ( 4.8A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 8
PHE B  55
VAL B   7
MET B  23
ILE B   5
1.62A16.96
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 8
PHE B  55
VAL B   7
MET B  23
ILE B   5
1.67A16.96
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 8
PHE C  55
VAL C   7
MET C  23
ILE C   5
1.77A16.96
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 8
PHE B  55
VAL B   7
MET B  23
ILE B   5
1.69A16.96
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 8
PHE B  55
VAL B   7
MET B  23
ILE B   5
1.69A16.96
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 7
GLU B 161
GLU B 167
TYR B 171
HIS B 175
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 8
PHE C  55
VAL C   7
MET C  23
ILE C   5
1.72A16.96
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 8
PHE C  55
VAL C   7
MET C  23
ILE C   5
1.75A16.96
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 8
PHE C  55
VAL C   7
MET C  23
ILE C   5
1.78A16.96
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
TYR F 268
VAL F 270
ILE F 292
ASN F 269
1.64A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
TYR E 268
VAL E 270
ILE E 292
ASN E 269
1.63A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 7
TYR B 268
VAL B 270
ILE B 292
ASN B 269
1.66A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 7
TYR A 268
VAL A 270
ILE A 292
ASN A 269
1.69A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 7
TYR C 268
VAL C 270
ILE C 292
ASN C 269
1.63A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
TYR A 268
VAL A 270
ILE A 292
ASN A 269
1.62A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
TYR A 268
VAL A 270
ILE A 292
ASN A 269
1.61A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
TYR F 268
VAL F 270
ILE F 292
ASN F 269
1.61A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
TYR A 268
VAL A 270
ILE A 292
ASN A 269
1.64A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
TYR B 268
VAL B 270
ILE B 292
ASN B 269
1.63A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 7
ILE A 292
HIS A 300
VAL A 350
PHE A 286
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
TYR D 268
VAL D 270
ILE D 292
ASN D 269
1.65A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
TYR E 268
VAL E 270
ILE E 292
ASN E 269
1.66A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 7
TYR D 268
VAL D 270
ILE D 292
ASN D 269
1.69A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
TYR E 268
VAL E 270
ILE E 292
ASN E 269
1.60A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
TYR F 268
VAL F 270
ILE F 292
ASN F 269
1.61A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 7
TYR D 268
VAL D 270
ILE D 292
ASN D 269
1.65A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
TYR B 268
VAL B 270
ILE B 292
ASN B 269
1.67A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
TYR E 268
VAL E 270
ILE E 292
ASN E 269
1.61A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 7
TYR B 268
VAL B 270
ILE B 292
ASN B 269
1.71A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
TYR A 268
VAL A 270
ILE A 292
ASN A 269
1.66A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
TYR F 268
VAL F 270
ILE F 292
ASN F 269
1.66A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 7
TYR C 268
VAL C 270
ILE C 292
ASN C 269
1.69A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 7
ILE C 292
HIS C 300
VAL C 350
PHE C 286
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
TYR B 268
VAL B 270
ILE B 292
ASN B 269
1.68A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 7
TYR F 268
VAL F 270
ILE F 292
ASN F 269
1.69A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
TYR C 268
VAL C 270
ILE C 292
ASN C 269
1.61A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 7
TYR A 268
VAL A 270
ILE A 292
ASN A 269
1.64A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 7
TYR E 268
VAL E 270
ILE E 292
ASN E 269
1.69A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
TYR C 268
VAL C 270
ILE C 292
ASN C 269
1.64A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 7
TYR E 268
VAL E 270
ILE E 292
ASN E 269
1.64A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
TYR D 268
VAL D 270
ILE D 292
ASN D 269
1.62A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 7
TYR F 268
VAL F 270
ILE F 292
ASN F 269
1.64A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
TYR C 268
VAL C 270
ILE C 292
ASN C 269
1.66A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
TYR D 268
VAL D 270
ILE D 292
ASN D 269
1.67A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 7
PHE C6985
TYR C7009
VAL C6965
ILE C6967
1.61A21.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 8
PHE C6985
TYR C7009
VAL C6965
ILE C6967
1.63A21.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 8
PHE A6985
TYR A7009
VAL A6965
ILE A6967
1.63A21.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_C_ZPCC1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
VAL A7087
ILE A7088
ASN A6920
GLU A7082
VAL A6894
1.70A21.93
None
None
FMT  A7106 (-3.8A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 7
PHE A6985
TYR A7009
VAL A6965
ILE A6967
1.61A21.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 7
PHE C6985
TYR C7009
VAL C6965
ILE C6951
1.74A21.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 8
PHE C6985
TYR C7009
VAL C6965
ILE C6951
1.72A21.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 8
PHE C6985
TYR C7009
VAL C6965
ILE C6967
1.64A21.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_C_ZPCC1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
VAL C7087
ILE C7088
ASN C6920
GLU C7082
VAL C6894
1.70A21.93
None
None
FMT  C7103 (-4.0A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 8
PHE A6985
TYR A7009
VAL A6965
ILE A6951
1.79A21.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 8
PHE A6985
TYR A7009
VAL A6965
ILE A6967
1.64A21.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 7
ILE D 157
TYR D 112
HIS D 145
PHE D 110
1.77A
None
None
ZN  D 202 (-3.4A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 7
ILE B 157
TYR B 112
HIS B 145
PHE B 110
1.75A
None
None
ZN  B 202 (-3.3A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 7
ILE C 157
TYR C 112
HIS C 145
PHE C 110
1.74A
None
None
ZN  C 201 (-3.4A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wkq NSP16
(SARS-CoV-2)		4 / 8
PHE A6985
TYR A7009
VAL A6965
ILE A6951
1.80A21.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wkq NSP16
(SARS-CoV-2)		4 / 8
PHE A6985
TYR A7009
VAL A6965
ILE A6967
1.64A21.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_C_ZPCC1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wkq NSP16
(SARS-CoV-2)		5 / 12
VAL C7086
ILE C7088
ASN C6920
GLU C7082
VAL C6894
1.80A21.93
None
None
FMT  C7106 ( 4.1A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_C_ZPCC1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wkq NSP16
(SARS-CoV-2)		5 / 12
VAL C7087
ILE C7088
ASN C6920
GLU C7082
VAL C6894
1.66A21.93
None
None
FMT  C7106 ( 4.1A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_C_ZPCC1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wkq NSP16
(SARS-CoV-2)		5 / 12
VAL A7086
ILE A7088
ASN A6920
GLU A7082
VAL A6894
1.77A21.93
None
None
FMT  A7109 ( 3.9A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wkq NSP16
(SARS-CoV-2)		4 / 7
PHE C6985
TYR C7009
VAL C6965
ILE C6967
1.61A21.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wkq NSP16
(SARS-CoV-2)		4 / 8
PHE C6985
TYR C7009
VAL C6965
ILE C6967
1.62A21.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wkq NSP16
(SARS-CoV-2)		4 / 7
PHE C6985
TYR C7009
VAL C6965
ILE C6951
1.74A21.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wkq NSP16
(SARS-CoV-2)		4 / 8
PHE C6985
TYR C7009
VAL C6965
ILE C6951
1.73A21.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wkq NSP16
(SARS-CoV-2)		4 / 7
PHE A6985
TYR A7009
VAL A6965
ILE A6967
1.62A21.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_C_ZPCC1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wkq NSP16
(SARS-CoV-2)		5 / 12
VAL A7087
ILE A7088
ASN A6920
GLU A7082
VAL A6894
1.67A21.93
None
None
FMT  A7109 ( 3.9A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wkq NSP16
(SARS-CoV-2)		4 / 8
PHE C6985
TYR C7009
VAL C6965
ILE C6967
1.63A21.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wkq NSP16
(SARS-CoV-2)		4 / 8
PHE A6985
TYR A7009
VAL A6965
ILE A6967
1.64A21.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 7
GLU A 261
HIS A 235
VAL A 295
PHE A 264
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 7
ILE A 223
TYR A 238
VAL A 295
PHE A 214
1.80A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 7
PHE A 233
TYR A 231
VAL A 304
GLU A 234
1.48A21.54
None
SO4  A 410 (-3.3A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 6
GLU A  42
PHE A  44
TYR A  33
VAL A  23
1.75A21.54
None
TRS  A 402 (-4.4A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 7
GLU A  42
PHE A  44
TYR A  33
VAL A  23
1.74A
None
TRS  A 402 (-4.4A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 7
PHE B 233
TYR B 231
VAL B 304
GLU B 234
1.48A21.54
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 7
GLU A  42
PHE A  44
TYR A  33
VAL A  23
1.63A
None
TRS  A 402 (-4.4A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 7
GLU B  42
PHE B  44
TYR B  33
VAL B  23
1.63A
EDO  B 411 (-4.9A)
TRS  B 402 (-4.5A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 6
ILE A  72
PHE A 123
TYR A 179
VAL A 149
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 8
PHE B 233
TYR B 231
VAL B 304
GLU B 234
1.51A21.54
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 7
GLU B  42
PHE B  44
TYR B  33
VAL B  23
1.74A
EDO  B 411 (-4.9A)
TRS  B 402 (-4.5A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 6
GLU B  42
PHE B  44
TYR B  33
VAL B  23
1.75A21.54
EDO  B 411 (-4.9A)
TRS  B 402 (-4.5A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 8
PHE A 233
TYR A 231
VAL A 304
GLU A 234
1.51A21.54
None
SO4  A 410 (-3.3A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 7
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.72A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 7
ILE A 200
PHE A 291
HIS A 172
VAL A 125
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.72A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.73A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 7
ILE A 106
TYR A 182
HIS A 164
PHE A 134
1.77A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.60A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 7
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.68A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.69A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 7
GLU A 178
PHE A 103
HIS A  80
VAL A  91
1.62A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
VAL C 155
ILE C  18
ASN C  20
GLU B 120
1.51A23.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
VAL C 155
ILE C  18
ASN C  20
GLU B 120
1.47A23.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
GLU B 120
PHE C 156
HIS C  45
VAL C  35
1.78A
None
APR  C 201 (-4.7A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
GLU D 120
PHE A 156
HIS A  45
VAL A  35
1.79A
APR  A 201 ( 4.7A)
APR  A 201 (-4.7A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
VAL A 155
ILE A  18
ASN A  20
GLU D 120
1.57A23.11
None
None
None
APR  A 201 ( 4.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
VAL C 155
ILE C  18
ASN C  20
GLU B 120
1.53A23.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 6
GLU D 120
PHE A 156
HIS A  45
VAL A  35
1.74A
APR  A 201 ( 4.7A)
APR  A 201 (-4.7A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
VAL C 155
ILE C  18
ASN C  20
GLU B 120
1.58A23.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
VAL A 155
ILE A  18
ASN A  20
GLU D 120
1.56A23.11
None
None
None
APR  A 201 ( 4.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
VAL C 155
ILE C  18
ASN C  20
GLU B 120
1.51A23.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
VAL C 155
ILE C  18
ASN C  20
GLU B 120
1.52A23.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
VAL A 155
ILE A  18
ASN A  20
GLU D 120
1.54A23.11
None
None
None
APR  A 201 ( 4.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
GLU D 120
PHE A 156
HIS A  45
VAL A  35
1.64A
APR  A 201 ( 4.7A)
APR  A 201 (-4.7A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
VAL A 155
ILE A  18
ASN A  20
GLU D 120
1.57A23.11
None
None
None
APR  A 201 ( 4.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 7
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.70A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 7
ILE A 200
PHE A 291
HIS A 172
VAL A 125
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 7
ILE A 106
TYR A 182
HIS A 164
PHE A 134
1.80A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.75A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 7
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.74A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.75A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.62A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.72A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6y2f REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 6
GLU A 178
PHE A 103
HIS A  80
VAL A  91
1.54A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.67A20.07
None
DMS  A 407 (-3.8A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.58A20.07
None
DMS  A 407 (-3.8A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
ILE A 200
PHE A 291
HIS A 172
VAL A 125
1.67A20.07
None
None
DMS  A 405 ( 4.8A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.65A20.07
None
DMS  A 407 (-3.8A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.70A20.07
None
DMS  A 407 (-3.8A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
TYR A 396
VAL A 512
ILE A 410
GLU A 516
1.62A22.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
TYR A 396
VAL A 512
ILE A 410
GLU A 516
1.55A22.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 6
GLU A 516
PHE A 429
TYR A 396
VAL A 341
1.67A22.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
PHE E 490
ARG E 454
ILE E 468
GLU E 484
1.63A22.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
TYR A 396
VAL A 512
ILE A 410
GLU A 516
1.53A22.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
GLU A 516
PHE A 429
TYR A 396
VAL A 341
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
PHE E 490
ARG E 454
ILE E 468
GLU E 484
1.64A22.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
PHE A 490
ARG A 454
ILE A 468
GLU A 484
1.62A22.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
TYR E 508
VAL E 510
ILE E 434
GLU E 406
1.72A22.74
DMS  E 902 (-4.0A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
GLU A 516
PHE A 429
TYR A 396
VAL A 341
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
GLU E 516
PHE E 515
TYR E 396
VAL E 341
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
PHE E 490
ARG E 454
ILE E 468
GLU E 484
1.54A22.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
TYR A 508
VAL A 510
ILE A 434
GLU A 406
1.79A22.74
DMS  A 903 (-3.5A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
TYR E 508
VAL E 510
ILE E 434
GLU E 406
1.78A22.74
DMS  E 902 (-4.0A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
GLU E 516
PHE E 515
TYR E 396
VAL E 341
1.63A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
TYR A 508
VAL A 510
ILE A 434
GLU A 406
1.72A22.74
DMS  A 903 (-3.5A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 6
GLU E 516
PHE E 515
TYR E 396
VAL E 341
1.62A22.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6ym0 SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
TYR E 508
VAL E 510
ILE E 434
GLU E 406
1.73A22.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6ym0 SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
PHE E 490
ARG E 454
ILE E 468
GLU E 484
1.67A22.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6ym0 SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
GLU E 516
PHE E 515
TYR E 396
VAL E 341
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6ym0 SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 6
GLU E 516
PHE E 515
TYR E 396
VAL E 341
1.57A22.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6ym0 SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
PHE E 490
ARG E 454
ILE E 468
GLU E 484
1.57A22.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6ym0 SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
TYR E 508
VAL E 510
ILE E 434
GLU E 406
1.67A22.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6ym0 SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
GLU E 516
PHE E 515
TYR E 396
VAL E 341
1.59A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6ym0 SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
PHE E 490
ARG E 454
ILE E 468
GLU E 484
1.49A22.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6ynq REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
GLU A 288
GLU A 290
PHE A 291
VAL A 125
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6ynq REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.59A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6ynq REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
GLU A 288
GLU A 290
PHE A 291
VAL A 125
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6ynq REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.67A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6ynq REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.66A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6ynq REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.72A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6ynq REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
ILE A 200
PHE A 291
HIS A 172
VAL A 125
1.61A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6ynq REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.71A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6ynq REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.71A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
GLU E 516
PHE E 515
TYR E 396
VAL E 341
1.63A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
GLU A 516
PHE A 515
TYR A 396
VAL A 341
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
TYR A 508
VAL A 510
ILE A 434
GLU A 406
1.72A21.77
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
PHE A 490
ARG A 454
ILE A 468
GLU A 484
1.62A21.77
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
PHE E 490
ARG E 454
ILE E 468
GLU E 484
1.64A21.77
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
TYR E 508
VAL E 510
ILE E 434
GLU E 406
1.79A21.77
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 6
GLU E 516
PHE E 515
TYR E 396
VAL E 341
1.61A21.77
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
GLU E 516
PHE E 515
TYR E 396
VAL E 341
1.63A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
PHE A 490
ARG A 454
ILE A 468
GLU A 484
1.63A21.77
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
PHE A 490
ARG A 454
ILE A 468
GLU A 484
1.53A21.77
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
TYR E 508
VAL E 510
ILE E 434
GLU E 406
1.72A21.77
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 6
GLU A 516
PHE A 515
TYR A 396
VAL A 341
1.62A21.77
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
PHE E 490
ARG E 454
ILE E 468
GLU E 484
1.63A21.77
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
TYR A 508
VAL A 510
ILE A 434
GLU A 406
1.79A21.77
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
PHE E 490
ARG E 454
ILE E 468
GLU E 484
1.54A21.77
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
GLU A 516
PHE A 515
TYR A 396
VAL A 341
1.63A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.68A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.70A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.75A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.61A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.73A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
ILE A 200
PHE A 291
HIS A 172
VAL A 125
1.62A
PEG  A 405 (-4.1A)
CL  A 406 (-4.4A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.73A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bqy MAIN PROTEASE
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.61A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bqy MAIN PROTEASE
(SARS-CoV-2)		4 / 7
ILE A 106
TYR A 182
HIS A 164
PHE A 134
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bqy MAIN PROTEASE
(SARS-CoV-2)		4 / 7
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.69A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bqy MAIN PROTEASE
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.73A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bqy MAIN PROTEASE
(SARS-CoV-2)		4 / 7
ILE A 200
PHE A 291
HIS A 172
VAL A 125
1.61A
None
None
PJE  C   5 (-4.4A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bqy MAIN PROTEASE
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.70A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bqy MAIN PROTEASE
(SARS-CoV-2)		4 / 6
ILE A 200
PHE A 291
HIS A 172
VAL A 125
1.72A
None
None
PJE  C   5 (-4.4A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bqy MAIN PROTEASE
(SARS-CoV-2)		4 / 7
GLU A 288
GLU A 290
PHE A 291
VAL A 125
1.62A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7btf NSP12
(SARS-CoV-2)		4 / 8
PHE A 219
TYR A 217
VAL A  96
GLU A  83
1.71A15.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7btf NSP12
(SARS-CoV-2)		4 / 6
GLU A  58
ILE A  66
PHE A  70
VAL A  96
1.26A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7btf NSP12
(SARS-CoV-2)		4 / 7
GLU A  58
ILE A  66
PHE A  70
VAL A  96
1.23A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7btf NSP12
(SARS-CoV-2)		5 / 8
PHE A 348
VAL A 535
ILE A 536
ASN A 657
GLU A 350
1.70A15.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7btf NSP8
(SARS-CoV-2)		4 / 8
PHE B 147
TYR B 149
VAL B 130
ILE B 132
1.78A19.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7btf NSP12
(SARS-CoV-2)		5 / 7
PHE A 348
VAL A 535
ILE A 536
ASN A 657
GLU A 350
1.66A15.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7btf NSP12
(SARS-CoV-2)		4 / 7
PHE A 348
VAL A 535
ILE A 536
ASN A 657
1.65A15.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7btf NSP12
(SARS-CoV-2)		4 / 8
PHE A 348
VAL A 535
ILE A 536
ASN A 657
1.64A15.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7btf NSP12
(SARS-CoV-2)		4 / 8
PHE A 348
VAL A 535
ILE A 536
GLU A 350
1.77A15.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7btf NSP8
(SARS-CoV-2)		4 / 7
PHE B 147
TYR B 149
VAL B 130
ILE B 132
1.76A19.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7btf NSP12
(SARS-CoV-2)		4 / 7
PHE A 219
TYR A 217
VAL A  96
GLU A  83
1.68A15.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7btf NSP12
(SARS-CoV-2)		4 / 7
PHE A 348
VAL A 535
ILE A 536
GLU A 350
1.61A15.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7btf NSP12
(SARS-CoV-2)		4 / 7
GLU A 136
TYR A 163
VAL A 174
PHE A 134
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7btf NSP12
(SARS-CoV-2)		4 / 7
GLU A  58
ILE A  66
PHE A  70
VAL A  96
1.21A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7btf NSP12
(SARS-CoV-2)		4 / 8
PHE A 219
TYR A 217
VAL A  96
GLU A  83
1.70A15.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7btf NSP8
(SARS-CoV-2)		4 / 8
PHE B 147
TYR B 149
VAL B 130
ILE B 132
1.79A19.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7btf NSP12
(SARS-CoV-2)		4 / 8
PHE A 219
TYR A 217
VAL A  96
GLU A  83
1.68A15.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7btf NSP8
(SARS-CoV-2)		4 / 8
PHE B 147
TYR B 149
VAL B 130
ILE B 132
1.78A19.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7btf NSP12
(SARS-CoV-2)		4 / 8
PHE A 348
VAL A 535
ILE A 536
ASN A 657
1.65A15.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7btf NSP12
(SARS-CoV-2)		4 / 8
PHE A 348
VAL A 535
ILE A 536
GLU A 350
1.61A15.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7btf NSP12
(SARS-CoV-2)		4 / 7
PHE A 219
TYR A 217
VAL A  96
GLU A  83
1.70A15.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		4 / 7
GLU A 178
TYR A 101
VAL A  18
PHE A 159
1.73A
None
None
DMS  A 403 ( 4.9A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.73A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		4 / 7
GLU A 288
GLU A 290
PHE A 291
VAL A 125
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		4 / 6
GLU A 178
PHE A 103
HIS A  80
VAL A  91
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.61A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.70A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		4 / 6
ILE A 200
PHE A 291
HIS A 172
VAL A 125
1.69A
None
None
DMS  A 402 (-4.4A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		4 / 7
GLU A 178
PHE A 103
HIS A  80
VAL A  91
1.46A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		4 / 7
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.68A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		4 / 7
ILE A 200
PHE A 291
HIS A 172
VAL A 125
1.58A
None
None
DMS  A 402 (-4.4A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		4 / 7
ILE A 106
TYR A 182
HIS A 164
PHE A 134
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
PHE A 348
VAL A 535
ILE A 536
GLU A 350
1.52A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
PHE A 348
VAL A 535
ILE A 536
GLU A 350
1.64A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
PHE A 348
VAL A 535
ILE A 536
ASN A 657
1.64A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv1 NSP8
(SARS-CoV-2)		4 / 8
PHE B 147
TYR B 149
VAL B 130
ILE B 132
1.79A18.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv1 NSP8
(SARS-CoV-2)		4 / 7
PHE B 147
TYR B 149
VAL B 130
ILE B 132
1.77A18.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv1 NSP8
(SARS-CoV-2)		4 / 8
PHE B 147
TYR B 149
VAL B 130
ILE B 132
1.74A18.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv1 NSP8
(SARS-CoV-2)		4 / 8
PHE B 147
TYR B 149
VAL B 130
ILE B 132
1.76A18.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv1 NSP8
(SARS-CoV-2)		4 / 8
PHE B 147
TYR B 149
VAL B 130
ILE B 132
1.77A18.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv1 NSP12
(SARS-CoV-2)		4 / 6
GLU A 136
TYR A 163
VAL A 174
PHE A 134
1.60A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_C_ZPCC1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv1 NSP12
(SARS-CoV-2)		5 / 12
PHE A 348
VAL A 535
ILE A 536
ASN A 657
GLU A 350
1.63A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
PHE A 480
VAL A 587
MET A 755
ILE A 757
1.59A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
PHE A 348
VAL A 535
ILE A 536
ASN A 657
1.64A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
PHE A 348
VAL A 535
ILE A 536
ASN A 657
1.64A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
PHE A 480
TYR A 479
VAL A 587
ILE A 589
1.79A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
PHE A 480
VAL A 587
MET A 755
ILE A 757
1.59A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
PHE A 480
VAL A 587
MET A 755
ILE A 757
1.64A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
PHE A 480
TYR A 479
VAL A 587
ILE A 589
1.78A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv1 NSP12
(SARS-CoV-2)		4 / 7
PHE A 480
TYR A 479
VAL A 587
ILE A 589
1.76A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv1 NSP12
(SARS-CoV-2)		4 / 7
GLU A 278
GLU A 277
HIS A 295
VAL A 354
1.71A
None
None
ZN  A1001 (-3.3A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
PHE A 480
VAL A 587
MET A 755
ILE A 757
1.61A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv1 NSP12
(SARS-CoV-2)		5 / 8
PHE A 348
VAL A 535
ILE A 536
ASN A 657
GLU A 350
1.64A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv1 NSP12
(SARS-CoV-2)		4 / 7
GLU A 278
GLU A 277
HIS A 295
VAL A 354
1.66A
None
None
ZN  A1001 (-3.3A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv1 NSP12
(SARS-CoV-2)		5 / 7
PHE A 348
VAL A 535
ILE A 536
ASN A 657
GLU A 350
1.60A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
PHE A 480
TYR A 479
VAL A 587
ILE A 589
1.71A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv1 NSP12
(SARS-CoV-2)		4 / 7
PHE A 348
VAL A 535
ILE A 536
GLU A 350
1.48A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv1 NSP8
(SARS-CoV-2)		4 / 7
PHE B 147
TYR B 149
VAL B 130
ILE B 132
1.73A18.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
PHE A 348
VAL A 535
ILE A 536
GLU A 350
1.49A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv1 NSP12
(SARS-CoV-2)		4 / 6
GLU A 277
PHE A 321
HIS A 295
VAL A 354
1.80A15.53
None
None
ZN  A1001 (-3.3A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv1 NSP12
(SARS-CoV-2)		4 / 7
GLU A 278
GLU A 277
HIS A 295
VAL A 354
1.69A
None
None
ZN  A1001 (-3.3A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv1 NSP12
(SARS-CoV-2)		4 / 7
PHE A 348
VAL A 535
ILE A 536
ASN A 657
1.66A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
PHE A 348
VAL A 535
ILE A 536
GLU A 350
1.74A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv2 NSP8
(SARS-CoV-2)		4 / 7
PHE B 147
TYR B 149
VAL B 130
ILE B 132
1.78A18.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
PHE A 480
VAL A 587
MET A 755
ILE A 757
1.58A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv2 NSP8
(SARS-CoV-2)		4 / 8
PHE B 147
TYR B 149
VAL B 130
ILE B 132
1.77A18.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
PHE A 480
VAL A 587
MET A 755
ILE A 757
1.57A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
PHE A 480
TYR A 479
VAL A 587
ILE A 589
1.78A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
PHE A 480
VAL A 587
MET A 755
ILE A 757
1.56A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv2 NSP12
(SARS-CoV-2)		4 / 7
GLU A 278
GLU A 277
HIS A 295
VAL A 354
1.77A
None
None
ZN  A1001 (-3.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
PHE A 348
VAL A 535
ILE A 536
ASN A 657
1.62A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv2 NSP12
(SARS-CoV-2)		4 / 7
GLU A 278
GLU A 277
HIS A 295
VAL A 354
1.79A
None
None
ZN  A1001 (-3.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv2 NSP12
(SARS-CoV-2)		4 / 7
GLU A 278
GLU A 277
HIS A 295
VAL A 354
1.71A
None
None
ZN  A1001 (-3.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_C_ZPCC1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv2 NSP12
(SARS-CoV-2)		5 / 12
PHE A 348
VAL A 535
ILE A 536
ASN A 657
GLU A 350
1.69A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
PHE A 348
VAL A 535
ILE A 536
ASN A 657
1.63A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv2 NSP12
(SARS-CoV-2)		4 / 7
PHE A 348
VAL A 535
ILE A 536
GLU A 350
1.60A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
PHE A 480
VAL A 587
MET A 755
ILE A 757
1.61A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
PHE A 348
VAL A 535
ILE A 536
GLU A 350
1.54A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv2 NSP8
(SARS-CoV-2)		4 / 8
PHE B 147
TYR B 149
VAL B 130
ILE B 132
1.75A18.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv2 NSP12
(SARS-CoV-2)		5 / 7
PHE A 348
VAL A 535
ILE A 536
ASN A 657
GLU A 350
1.66A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
PHE A 348
VAL A 535
ILE A 536
GLU A 350
1.59A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv2 NSP8
(SARS-CoV-2)		4 / 7
PHE B 147
TYR B 149
VAL B 130
ILE B 132
1.74A18.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv2 NSP12
(SARS-CoV-2)		4 / 7
PHE A 441
VAL A 844
ILE A 847
ASN A 414
1.73A15.53
None
None
U  P  17 ( 3.8A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv2 NSP12
(SARS-CoV-2)		4 / 7
PHE A 480
TYR A 479
VAL A 587
ILE A 589
1.76A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv2 NSP8
(SARS-CoV-2)		4 / 8
PHE B 147
TYR B 149
VAL B 130
ILE B 132
1.76A18.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv2 NSP8
(SARS-CoV-2)		4 / 8
PHE B 147
TYR B 149
VAL B 130
ILE B 132
1.80A18.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
PHE A 480
TYR A 479
VAL A 587
ILE A 589
1.78A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv2 NSP12
(SARS-CoV-2)		4 / 7
ILE A 632
GLU A 350
PHE A 348
HIS A 295
1.68A
None
None
None
ZN  A1001 (-3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
PHE A 480
TYR A 479
VAL A 587
ILE A 589
1.70A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv2 NSP12
(SARS-CoV-2)		4 / 6
GLU A 136
TYR A 163
VAL A 174
PHE A 134
1.61A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
PHE A 348
VAL A 535
ILE A 536
ASN A 657
1.61A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv2 NSP12
(SARS-CoV-2)		4 / 7
GLU A 136
TYR A 163
VAL A 174
PHE A 134
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv2 NSP12
(SARS-CoV-2)		4 / 7
PHE A 348
VAL A 535
ILE A 536
ASN A 657
1.63A15.53
None